Merck & Co., Inc.
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$349.4M
Q ending 2026-03-31
Prior quarter
$276.3M
Q ending 2025-12-31
Change
+26.5% QoQ · +112.7% YoY
Positions
14
reported holdings
Largest positions
All 14 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Moderna Inc | MRNA | Shares | $117.3M | 2.3M |
| Personalis Inc | PSNL | Shares | $89.5M | 14.0M |
| Kymera Therapeutics Inc | KYMR | Shares | $64.3M | 772K |
| Entrada Therapeutics Inc | Shares | $22.0M | 1.7M | |
| Eikon Therapeutics Inc | EIKN | Shares | $17.6M | 1.7M |
| Aktis Oncology Inc | AKTS | Shares | $17.0M | 953K |
| Alector Inc | ALEC | Shares | $7.6M | 3.5M |
| Sutro Biopharma Inc | Shares | $6.8M | 272K | |
| Evaxion Biotech A/S | EVAXUSD | Shares | $4.5M | 1.2M |
| Viridian Therapeutics Inc | VRDN | Shares | $1.8M | 93K |
| Xilio Therapeutics Inc | XLO | Shares | $891K | 106K |
| Carisma Therapeutics Inc | CARM | Shares | $48K | 1.5M |
| Neuphoria Therapeutics Inc | NEUP | Shares | $41K | 10K |
| Tuhura Biosciences | HURA | Shares | $35K | 19K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.